Ubiquitin Ligase Mechanisms in Cancer Cell Regulation

The ubiquitin–proteasome system orchestrates pivotal regulatory pathways in cancer cells by marking key proteins for destruction or stabilisation. Central to this machinery are E3 ubiquitin ligases, multi-subunit complexes that confer substrate specificity through dedicated receptor subunits. Among these, SCF (SKP1–Cullin1–F-box) complexes harness F-box proteins such as FBXW7, SKP2 and β-TrCP to recognise phosphorylated degron motifs and catalyse polyubiquitination, thereby governing cell-cycle progression, DNA repair, apoptosis and signal transduction. Aberrant function of E3 ligases or their regulatory partners can drive oncogenesis through stabilisation of oncoproteins or degradation of tumour suppressors. Moreover, deubiquitinases counterbalance ligase activity by removing ubiquitin chains, offering additional layers of control. Recent advances have illuminated dynamic crosstalk within ligase networks, uncovered novel substrate receptors and exposed feedback loops that modulate ligand turnover. These mechanisms underpin therapeutic strategies aimed at restoring proteostatic balance, exemplified by molecular glues that reprogramme ligase specificity or small molecules that stabilise tumour-suppressive F-box proteins. Together, these insights highlight the nuanced roles of ubiquitin ligases in cancer cell regulation and underscore their growing significance as drug targets.

Research from Nature Portfolio

Studies have delineated a three-component cascade involving β-TrCP, FBXW2 and SKP2 that modulates lung cancer cell growth. In this axis, β-TrCP catalyses ubiquitination and turnover of FBXW2, while FBXW2 reciprocally targets SKP2 for degradation. The inverse oscillation of these ligases during cell-cycle phases ensures that FBXW2 accumulates in arrested cells to restrain SKP2-driven proliferation, whereas proliferative cues shift the balance towards SKP2 stability. Mutational analyses reveal that loss-of-function alleles of FBXW2 are recurrent in tumours, correlating with heightened SKP2 levels and poor patient prognosis. Restoration of FBXW2 expression suppresses oncogenic signalling and reinstates cell-cycle checkpoints, underscoring its tumour-suppressive role within a broader ligase network.

Ubiquitin Ligase Mechanisms in Cancer Cell Regulation publication trend

The graph below shows the total number of articles in ubiquitin ligase mechanisms in cancer cell regulation across all publications each year (not limited to Nature Index journals).

Technical terms

Ubiquitination: Covalent attachment of ubiquitin molecules to a substrate, marking it for proteasomal degradation or functional modulation.

E3 ubiquitin ligase: Enzyme complex that recognises specific substrates and catalyses transfer of ubiquitin from E2 conjugating enzymes.

F-box protein: Substrate receptor subunit of SCF ligases, containing an F-box motif for SKP1 binding and domains for degron recognition.

SCF complex: Multi-protein E3 ligase comprising SKP1, Cullin1, RING protein and an F-box receptor, orchestrating targeted ubiquitination.

Deubiquitinase: Enzyme that removes ubiquitin chains from substrates, counteracting E3 ligase activity to stabilise proteins.

Degron: Short peptide motif within a protein that is recognised by an E3 ligase receptor to initiate ubiquitination.

Epithelial–mesenchymal transition (EMT): Phenotypic shift in epithelial cells towards a migratory and invasive mesenchymal state, facilitating metastasis.

References

1. All‐Trans Retinoic Acid Promotes a Tumor Suppressive OTUD6B‐β‐TrCP‐SNAIL Axis in Esophageal Squamous Cell Carcinoma and Enhances Immunotherapy. Advanced Science (2023).
2. Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasis. Experimental Hematology & Oncology (2024).
3. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nature Communications (2017).